Chronic inflammatory demyelinating polyradiculoneuropathy: Search for factors associated with treatment dependence or successful withdrawal

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 85, Issue 8, 2014, Pages 899-904

  Rabin, Magalie ^a   Mutlu, Gurkam ^a   Stojkovic, Tanya ^a   Maisonobe, Thierry ^a   Lenglet, Timothée ^a   Fournier, Emmanuel ^a   Bouche, Pierre ^a   Leǵer, Jean Marc ^a   Viala, Karine ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; ANTIINFLAMMATORY AGENT;

ADOLESCENT; ADULT; AGED; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVOUS SYSTEM ELECTROPHYSIOLOGY; OUTCOME ASSESSMENT; PHARMACEUTICAL CARE; POLYRADICULONEUROPATHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; TREATMENT DEPENDENCE; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; AGE; ARTICLE; DISEASE COURSE; ELECTRODIAGNOSIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUROPATHY; RECURRENT DISEASE; SEX DIFFERENCE; TREATMENT OUTCOME;

NEUROPATHY;

ADRENAL CORTEX HORMONES; ADULT; AGE FACTORS; ANTI-INFLAMMATORY AGENTS; DISEASE PROGRESSION; ELECTRODIAGNOSIS; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; RECURRENCE; RETROSPECTIVE STUDIES; SEX FACTORS; TREATMENT OUTCOME;

EID: 84906716650     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2013-306105     Document Type: Review

References (21)

1. Van Den Bergh PYK, Hadden RDM, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - First Revision Members of the Task Force. Eur J Neurol 2010;17:356-63.
2. Dyck PJ, Daube J, O'Brien P, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986;314:461-5. (Pubitemid 16161945)
3. Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994;36:838-45. (Pubitemid 24370922)
4. Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996;119:1055-66. (Pubitemid 26300708)
5. Hahn AF, Bolton CF, Zochodne D, et al. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo controlled, cross-over study. Brain 1996;119:1067-77. (Pubitemid 26300709)
6. Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIG in untreated CIDP. Neurology 2001;56:445-9.
7. Hughes RAC, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50:195-201. (Pubitemid 32738144)
8. Viala K, Maisonobe T, Stojkovic T, et al. A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy. J Periph Nerv Syst 2010;15:50-6.
9. Querol L, Rojas-Garcia R, Casasnovas C, et al. Long-term outcome in CIDP patients treated with IVIG: a retrospective study. Muscle Nerve 48:870-6.
10. Kuwabara S, Misawa S, Mori M, et al. Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases. J Neurol Neurosurg Psychiatry 2006;77:66-70. (Pubitemid 43022693)
11. Hughes RAC, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008;7:136-44.
12. Hughes RA, Gorson KC, Cros D, et al. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2010;74:651-7.
13. Van Schaik IN, Eftimov F, Van Doorn PA, et al. Pulsed high dose dexamethsone versus standard prednisolone treatment for CIDP (PREDICT study): a double blind, randomised, controlled trial. Lancet Neurol 2010;9:245-53.
14. Nobile-Orazio E, Cocito D, Jann S, et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol 2012;11:493-502.
15. RMC Trial Group. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol 2009;8:158-64.
16. Viala K, Renie L, Maisonobe T, et al. Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome. Brain 2004;127:2010-17. (Pubitemid 39150259)
17. R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2008. ISBN 3-900051-07-0. http://www.R-project.org
18. Therneau TM, Atkinson B. R port by Brian Ripley. Rpart: Recursive Partitioning. R package version 3.1-41. 2008. http://mayoresearch.mayo.edu/mayo/ research/biostat/splusfunctions.cfm
19. Nobile-Orazio E, Cocito D, Jann S, et al. Frequency and time to relapse after therapy discontinuation in CIDP patients treated for six months with IVIG or IV methylprednisolone (IMC study follow-up). J Peripher Nerv Syst 2013;18(Suppl):S80-1.
20. Eftimov F, Vermeulen M, van Doorn PA, et al. Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology 2012;78:1079-84.
21. Attarian S, Verschueren A, Franques J, et al. Response to treatment in patients with Lewis-Sumner syndrome. Muscle Nerve 2011;44:179-84.